# Phase 4c Report: Final Batch Compatibility Audit
**Date:** 2026-06-02
**Topic:** heat-cold-thermoregulation (final integration batch)

## Method

Grep-based mechanism term matching across 24 new environments vs full hypothesis registry.

## Results

| Metric | Count |
|--------|-------|
| New environments | 24 |
| Registry hits (any term) | 12 |
| Reinforcement pairs | 3 (HSP70 induction reinforces existing HSP70 entries; ET-1 supplementation reinforces existing ET-1 speculation; magnesium reinforces existing magnesium entry) |
| Feed-into chains | 2 (glycine→ET-1 reduction→vasomotor flexibility; cold adaptation→BAT recruitment→cold tolerance) |
| Conflicts | 0 |
| Independents | 19 (novel substance/combination/model with no existing registry entry) |

## Reinforcement Details

1. **spec:ala-hsp70 + spec:sulforaphane-hsp70** → reinforce existing HSP70 dysregulation entry (universal-mechanisms) and existing Hochecker-based hyperthermia entries. Same pathway (HSP70 induction), different route (pharmacological vs thermal). Non-conflicting.

2. **spec:magnesium-glycinate-thermoreg + spec:glycine-vascular-thermoreg** → reinforce existing ET-1 speculation (registry line 741). Both target ET-1-mediated vasoconstriction via complementary mechanisms (magnesium: vascular smooth muscle relaxation; glycine: endothelial glycine receptor vasodilation).

3. **spec:creatine-thermoreg-atp** → reinforces existing creatine entries in supplement chapter. New claim is specific to thermoregulatory ATP buffering — not contradicted by existing content.

## Certainty Adjustments

None. All new environments have cert 0.20-0.35. Existing reinforced entries unaffected (each reinforcement comes from a low-certainty source below the 0.60 Evidence Quality Floor for bumps).

## Zero Conflicts

The 19 independent entries are in domains with no existing registry hypotheses (specific supplements like carnitine/citrulline, drug repurposing like roflumilast/4-PB, combination protocols, math models). No mechanism-level conflict is possible when there's no prior claim to contradict.
